Human Recombinant Insulin Market Size (2024 - 2029)

The human recombinant insulin market is projected to experience growth driven by the increasing prevalence of diabetes globally, exacerbated by the COVID-19 pandemic. The heightened risk of severe COVID-19 infections among diabetes patients has intensified the demand for insulin therapies. Additionally, factors such as obesity and reduced physical activity, which are significant contributors to Type 2 diabetes, are further fueling the need for effective diabetes management solutions. This growing demand is particularly pronounced in regions with limited healthcare resources, underscoring the market's expansion potential.

Market Size of Human Recombinant Insulin Industry

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:
Human Recombinant Insulin Market Summary
Study Period 2018 - 2029
Market Size (2024) USD 28.47 Billion
Market Size (2029) USD 32.20 Billion
CAGR (2024 - 2029) 2.90 %
Fastest Growing Market Asia Pacific
Largest Market North America

Major Players

Human Recombinant Insulin Market Major Players

*Disclaimer: Major Players sorted in no particular order

Need a report that reflects how COVID-19 has impacted this market and its growth?

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Human Recombinant Insulin Market Analysis

The Human Recombinant Insulin Market size is estimated at USD 28.47 billion in 2024, and is expected to reach USD 32.20 billion by 2029, growing at a CAGR of greater than 2.9% during the forecast period (2024-2029).

COVID-19 is expected to drive the growth of the market during the forecast period. The increased risk for diabetes patients during the COVID-19 outbreak is expected to drive the demand for the human recombinant insulin market. For instance, the article titled ' COVID-19 and Diabetes' published in December 2020 mentioned that about 25% of people who visited the hospital with severe COVID-19 infections had diabetes. Additionally, the article titled ' COVID-19 and Diabetes: Understanding the Interrelationship and Risks for a Severe Course' published in June 2021 mentioned that Patients with diabetes are known to have an increased risk of infections particularly respiratory tract infects such as SARS-CoV-2. Thus, the outbreak of COVID-19 is expected to drive the growth of the market during the pandemic period.

The factors such as the increasing prevalence of diabetes across the world are expected to drive the growth of the market during the forecats period. Diabetes is one of the most malignant diseases of the 21st century. According to the World Health Organization, it has been predicted that diabetes is likely to be the seventh most leading cause of death by 2030.

Furthermore, obesity is the most potent factor for Type 2 diabetes, which accounts for 80-85% of the overall risk of developing Type 2 diabetes. In April 2022, United States National Center for Chronic Disease Prevention and Health Promotion updated its article on physical inactivity and estimated that the reduction in physical activity is one of the major factors causing diseases such as type II diabetes. Hence, due to the exponential rise in the prevalence of diabetes, there is an urgent demand for establishing effective diabetes therapy in countries, which are burdened by inadequate health care budgets, malnutrition, and infectious diseases which is augmenting the demand for human recombinant insulin and the market is majorly driven by the same factor.

Human Recombinant Insulin Industry Segmentation

As per the scope of the report, recombinant human insulin has replaced animal insulin and animal-based semi synthetic human insulin, which are available in sufficient quantities and at affordable prices, in order to provide global access to insulin therapy. The human recombinant insulin market is segmented by drug (short-acting human insulin, intermediate-acting human insulin, and premixed human insulin), brand (Insuman, Humulin, Novolin, and other brands), and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and Latin America). The market report also covers the estimated market sizes and trends for different countries across major regions and globally. The report offers the value (in USD) and volume (in unit mL) for the above segments. The report will provide a segment-wise breakdown (value and volume) for all the countries covered under the table of contents.

Drug
Short-acting Human Insulin
Intermediate-acting Human Insulin
Premixed Human Insulin
Brand
Insuman
Humulin
Novolin
Other Brands
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Australia
Vietnam
Malaysia
Indonesia
Philippines
Thailand
Rest of Asia-Pacific
Middle East and Africa
Saudi Arabia
Iran
Egypt
Oman
South Africa
Rest of Middle East and Africa
Latin America
Mexico
Brazil
Rest of Latin America
Need A Different Region Or Segment?
Customize Now

Human Recombinant Insulin Market Size Summary

The human recombinant insulin market is poised for significant growth, driven by the increasing prevalence of diabetes globally and the heightened demand for effective diabetes management solutions. The COVID-19 pandemic has further accelerated this demand, as individuals with diabetes face a higher risk of severe infections, including those caused by the SARS-CoV-2 virus. This has underscored the critical need for reliable insulin therapies. The market is characterized by the use of advanced recombinant DNA technology, with products like Humulin playing a pivotal role due to their structural similarity to human insulin and their ability to meet the therapeutic needs of diabetes patients. Despite some challenges related to adverse reactions, the accessibility and ongoing healthcare investment in such products are expected to sustain market growth.

North America is anticipated to be a major contributor to the market's expansion, driven by the region's high diabetes prevalence and the active involvement of key market players. The United States, in particular, faces a growing diabetic population, exacerbated by obesity and sedentary lifestyles, which fuels the demand for diabetes therapeutics. The market's consolidation is evident with dominant players like Eli Lilly and Company, Novo Nordisk, and Sanofi S.A. leading the charge. Additionally, innovations such as the use of rDNA technology to produce synthetic insulin are expected to lower costs and enhance accessibility, further propelling market growth. The ongoing product launches and strategic partnerships, such as those by Biocon Biologics, are also set to strengthen the market landscape during the forecast period.

Explore More

Human Recombinant Insulin Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

    3. 1.3 Market Restraints

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Bargaining Power of Buyers/Consumers

      2. 1.4.2 Bargaining Power of Suppliers

      3. 1.4.3 Threat of New Entrants

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION

    1. 2.1 Drug

      1. 2.1.1 Short-acting Human Insulin

      2. 2.1.2 Intermediate-acting Human Insulin

      3. 2.1.3 Premixed Human Insulin

    2. 2.2 Brand

      1. 2.2.1 Insuman

      2. 2.2.2 Humulin

      3. 2.2.3 Novolin

      4. 2.2.4 Other Brands

    3. 2.3 Geography

      1. 2.3.1 North America

        1. 2.3.1.1 United States

        2. 2.3.1.2 Canada

        3. 2.3.1.3 Mexico

      2. 2.3.2 Europe

        1. 2.3.2.1 Germany

        2. 2.3.2.2 United Kingdom

        3. 2.3.2.3 France

        4. 2.3.2.4 Italy

        5. 2.3.2.5 Spain

        6. 2.3.2.6 Rest of Europe

      3. 2.3.3 Asia-Pacific

        1. 2.3.3.1 China

        2. 2.3.3.2 Japan

        3. 2.3.3.3 India

        4. 2.3.3.4 Australia

        5. 2.3.3.5 South Korea

        6. 2.3.3.6 Australia

        7. 2.3.3.7 Vietnam

        8. 2.3.3.8 Malaysia

        9. 2.3.3.9 Indonesia

        10. 2.3.3.10 Philippines

        11. 2.3.3.11 Thailand

        12. 2.3.3.12 Rest of Asia-Pacific

      4. 2.3.4 Middle East and Africa

        1. 2.3.4.1 Saudi Arabia

        2. 2.3.4.2 Iran

        3. 2.3.4.3 Egypt

        4. 2.3.4.4 Oman

        5. 2.3.4.5 South Africa

        6. 2.3.4.6 Rest of Middle East and Africa

      5. 2.3.5 Latin America

        1. 2.3.5.1 Mexico

        2. 2.3.5.2 Brazil

        3. 2.3.5.3 Rest of Latin America

Human Recombinant Insulin Market Size FAQs

The Human Recombinant Insulin Market size is expected to reach USD 28.47 billion in 2024 and grow at a CAGR of greater than 2.9% to reach USD 32.20 billion by 2029.

In 2024, the Human Recombinant Insulin Market size is expected to reach USD 28.47 billion.

Human Recombinant Insulin Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)